AbbVie and Genmab reported a Phase 3 combination success for Epkinly (epcoritamab) with lenalidomide in diffuse large B-cell lymphoma. The Epcore DLBCL-4 trial met its primary endpoint by reducing the risk of progression or death by 60% versus the R-GemOx regimen, using FDA censoring rules for the headline figure; non-U.S. regulators saw a similar progression-free survival improvement at 56%. The companies did not provide overall survival details in the initial release. They also said the safety profile aligned with known risks for the individual agents. The result follows an earlier monotherapy setback in Epcore DLBCL-1 that had pressured investor sentiment. The win keeps the program positioned for a high-stakes readout in the first-line setting, where competition in CD20xCD3 T-cell engager space remains intense.